PTOISB08s (08-03)
Approved for use through 07/31/0006 ONE 0651-0001
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMS control number.

NFORMATION DISCLOSURE	Application Number		10567212	
	Filing Date			
	First Named Inventor DECL		AN P. KELLY	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit			
Not for submission under 57 of K 1.337	Examiner Name			
	Attorney Docket Numb	er	NL030952	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup> Issue Date Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev				
	1										
If you wis	h to a	dd additional U.S. Pater							Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	of cited Document		Releva		Lines where ges or Relev	
	1	20020049677	A1	2002-04	1-25	YAMADA ET /	NL.				
	2	20020136411	A1	2002-09	1-26	ISHIGURO ET	AL				
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>			Publication Date	Name of Patentee or Applicant of cited Document		vhere Rel	or Relevant	Τ.
	1	1211686	ΕP		A2	2002-06-05	SONY CORP				С
	2	1388857	EP		A1	2004-02-11	PIONEER CORP				

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Learning Name Attorney Docket Number | No 109952

A2 2004-03-18

2004023474

wo

MATSUSHITA

ELECTRIC IND. CO.

Date Considered

	4	199526028	wo		1995-09-28	GMS LIMITED					
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.										
	1	*EXPIRING DVD REGION LOCKS*, PAGE 1, PARA 3. www.halfbakery.com/dea/expring_20DVD_20hegion_20locks.									
	2 ISR: PCT/IB04051339										
	3	WRITTEN OPINION: PO	CT/IB04/051339								

See Kinz Octor of USPTO Patent Documents at wore USPTO.GOV or MPEP 90.0A. I Enter office that issued the document, by the two-lefter code (WIPO Secolard ST.3.) \*Fox Appendix potent of the patent document and the patent document which is present and preced the serial number of the patent document work with the patent document and the patent document work with the patent document and the patent document work with the patent document and the patent document work with the patent document and the patent docume

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567212
Filing Date		
First Named Inventor DECL		AN P. KELLY
Art Unit		
Examiner Name		
Attorney Docket Number		NL030952

### CERTIFICATION STATEMENT

Please see	37	CFR 4	97	and	1 02	to	make the	annron	viote	بمامه	rtion	(e)	ı

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 137(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/MICHAEL E. BELK	Date (YYYY-MM-DD)	2007-09-10
Name/Print	MICHAEL E. BELK	Registration Number	33357

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.